💊 Tax Relief Sparks Fresh Interest in Jubilant Pharmova!

$JUBLPHARMA is likely to remain in focus today after its subsidiary, Jubilant Generics, received a favorable rectification order for Assessment Year 2023-24. The order significantly reduces the total tax adjustments from ₹107.89 crore to ₹42.41 crore, providing substantial relief to the company. In addition, Jubilant Generics has secured relief from the relevant transfer pricing officer, resulting in the restoration of tax losses worth ₹65.48 crore. The development strengthens the subsidiary’s tax position and could improve financial flexibility going forward. Investors may keep a close watch on the stock as the positive tax outcome enhances sentiment around the company. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.